Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00HTY
|
||||
| Former ID |
DIB018020
|
||||
| Drug Name |
PGF2alpha
|
||||
| Synonyms |
Amoglandin; Cerviprost; Cyclosin; Enzaprost; Panacelan; prostaglandin F2alpha
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] | Clinical trial | [532003] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C20H34O5
|
||||
| InChI |
InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,18-,19+/m0/s1
|
||||
| InChIKey |
PXGPLTODNUVGFL-YNNPMVKQSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
3912, 613198, 4265953, 7847149, 7980284, 8143215, 8616237, 14852168, 15398784, 26754609, 29216066, 39289529, 47588758, 47588759, 48258963, 48415906, 50026801, 50110092, 53789218, 56311306, 56313004, 56313208, 57357710, 77668180, 92308787, 92309910, 99300824, 99302342, 103214323, 103943633, 104046437, 113853160, 124892254, 124892255, 125307573, 126662422, 134340899, 134978425, 135651540, 137006907, 142063920, 144205330, 162205063, 175268163, 175607780, 176484109, 179116866, 211534905, 223673680, 226412676
|
||||
| Target and Pathway | |||||
| Target(s) | Prostaglandin F2-alpha receptor | Target Info | Agonist | [526505] | |
| Putative G-protein coupled receptor 44 | Target Info | Agonist | [526611] | ||
| Thromboxane A2 receptor | Target Info | Agonist | [525673] | ||
| Prostaglandin E2 receptor, EP1 subtype | Target Info | Agonist | [534595] | ||
| Prostaglandin E2 receptor EP3 subtype | Target Info | Agonist | [534478] | ||
| Prostaglandin E2receptor, EP2 subtype | Target Info | Agonist | [525571] | ||
| Prostaglandin E2 receptor, EP4 subtype | Target Info | Agonist | [534595] | ||
| Prostaglandin D2 receptor | Target Info | Agonist | [525673] | ||
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interactionhsa04020:Calcium signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Platelet activationhsa04020:Calcium signaling pathway | |||||
| Pathways in cancerhsa04020:Calcium signaling pathway | |||||
| cAMP signaling pathway | |||||
| Regulation of lipolysis in adipocytes | |||||
| Pathways in cancerhsa04024:cAMP signaling pathway | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| Renin secretion | |||||
| Pathways in cancerhsa04080:Neuroactive ligand-receptor interaction | |||||
| PANTHER Pathway | PI3 kinase pathway | ||||
| Pathway Interaction Database | Thromboxane A2 receptor signaling | ||||
| PathWhiz Pathway | Intracellular Signalling Through PGD2 receptor and Prostaglandin D2 | ||||
| Reactome | Prostanoid ligand receptors | ||||
| G alpha (q) signalling eventsR-HSA-391908:Prostanoid ligand receptors | |||||
| G alpha (i) signalling eventsR-HSA-391908:Prostanoid ligand receptors | |||||
| G alpha (q) signalling events | |||||
| G alpha (12/13) signalling events | |||||
| Thromboxane signalling through TP receptorR-HSA-391908:Prostanoid ligand receptors | |||||
| G alpha (s) signalling eventsR-HSA-391908:Prostanoid ligand receptors | |||||
| G alpha (s) signalling events | |||||
| WikiPathways | Prostaglandin Synthesis and Regulation | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Small Ligand GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, OtherWP455:GPCRs, Class A Rhodopsin-like | |||||
| GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like | |||||
| Signal amplification | |||||
| GPCR downstream signalingWP98:Prostaglandin Synthesis and Regulation | |||||
| Ovarian Infertility Genes | |||||
| Vitamin D Receptor Pathway | |||||
| References | |||||
| Ref 525571 | Importance of the extracellular domain for prostaglandin EP(2) receptor function. Mol Pharmacol. 1999 Sep;56(3):545-51. | ||||
| Ref 525673 | The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. | ||||
| Ref 526505 | Identification by site-directed mutagenesis of amino acids contributing to ligand-binding specificity or signal transduction properties of the human FP prostanoid receptor. Biochem J. 2003 Apr 15;371(Pt 2):443-9. | ||||
| Ref 526611 | Expression and molecular pharmacology of the mouse CRTH2 receptor. J Pharmacol Exp Ther. 2003 Aug;306(2):463-70. Epub 2003 Apr 29. | ||||
| Ref 534478 | Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. | ||||
| Ref 534595 | Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.